- Patent Title: Fluorene derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition comprising same as effective ingredient for preventing or treating HCV-related disease
-
Application No.: US16633382Application Date: 2018-09-20
-
Publication No.: US11261175B2Publication Date: 2022-03-01
- Inventor: Byeong Moon Kim , Sung Key Jang , Young Su You , Il Hak Bae , Heejo Moon , Byeong Wook Kim , Hee Sun Kim , Jaegon Mun
- Applicant: Seoul National University R&DB Foundation , Postech Academy-Industry Foundation
- Applicant Address: KR Seoul; KR Gyeongsangbuk-do
- Assignee: Seoul National University R&DB Foundation,Postech Academy-Industry Foundation
- Current Assignee: Seoul National University R&DB Foundation,Postech Academy-Industry Foundation
- Current Assignee Address: KR Seoul; KR Gyeongsangbuk-do
- Agency: Licata & Tyrrell P.C.
- Priority: KR10-2017-0122791 20170922
- International Application: PCT/KR2018/011182 WO 20180920
- International Announcement: WO2019/059687 WO 20190328
- Main IPC: C07D403/12
- IPC: C07D403/12 ; A23L33/10 ; A61P31/14 ; C07D403/14 ; C07D413/14 ; C07D491/113 ; C07D519/00

Abstract:
The present invention relates to a fluorene derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition comprising the same as an effective ingredient for preventing or treating HCV-related disease. A fluorene derivative according to the present invention is identified to exhibit an antiviral performance against not only HCV, but also highly against HCV mutants, particularly double mutants and thus can be used in a pharmaceutical composition for prevention or treatment of HCV-caused liver disease, such as acute hepatitis C, chronic hepatitis C, liver cirrhosis, hepatocellular cancer, etc., particularly, liver disease caused by mutants of HCV. The derivative can be useful in a pharmaceutical composition for prevention or treatment of HCV-related liver disease by which the problem of resistant mutation against conventional therapeutic agents is solved.
Public/Granted literature
Information query